
Lanevskyi / Shutterstock.com
Around 6.4 million prescriptions per month could have been affected by medicines shortages in 2026, the National Pharmacy Association (NPA) has said, as it urged the government to publish its response to a 2025 consultation on pharmacist dispensing flexibilities.
In a press release issued on 17 November 2026, the NPA said its calculation was based on an analysis of Department of Health and Social Care (DHSC) data on 14 medicine supply notifications (MSNs), which could have caused an impact on up to 6.4 million prescription items, as the MSNs included commonly-prescribed medications such as co-codamol, Estradot and ramipril.
“Pharmacies have urged the government to publish its consultation response, which closed nearly a year ago, to allow pharmacists to make substitutions to prescriptions when a medicine is not in stock,” it added.
On 15 October 2026, the Pharmacy All Party Parliamentary Group also called on the government to publish its response to the consultation, which closed in December 2025. At the time, the DHSC told The Pharmaceutical Journal that it planned to set out the next steps regarding the consultation “in the coming weeks”.
In its press release, the NPA also urged health secretary Yvette Cooper to “publish an urgent action plan to tackle the growing problem of medicine shortages and improve the UK’s resilience to medicine supply disruption”.
Olivier Picard, chair of the NPA, said: “Problems with medicine supply can not only cause significant anxiety and frustration for patients but also can pose a serious safety risk, particularly for time-critical medicines such as insulin and some antiepileptic treatments.
“We are looking at a perfect storm of medicine supply challenges, coupled with soaring prices with pharmacy owners all too often footing the bill of our medicines.
“The new secretary of state must grip this problem head on. This includes overturning mad rules that stop pharmacists from making any changes to a prescription when a medicine is out of stock, forcing a patient to go back to their GP.”
In July 2026, the number of price concessions granted by the government — an indication of medicines shortages — reached a record 254, while the most recent figures, which are for October 2026, show that there were 245 concessions granted.
On 16 November 2026, the Company Chemists’ Association (CCA) responded to reports that the UK and the EU could reach an agreement to share information on medicine shortages.
In comments made to the press, Malcolm Harrison, chief executive of the CCA, said: “Better information sharing should help the UK to anticipate supply problems and respond more quickly when they emerge — but it will not address the underlying problem.
“Successive governments have sought to drive down the price they pay for medicines, especially generic medicines, which make up around four-fifths of all NHS-prescribed medicines. Whilst this has saved the taxpayer money, it has also led to some manufacturers and suppliers prioritising other global markets.
“The government must recognise the value and not just the cost of medicines. They need to invest in medicines pricing and community pharmacies, which buy and supply around 1.2 billion NHS-prescribed items each year.”
In its report — entitled, ‘Medicines shortages: one year on’, published on 24 March 2026 — the Royal College of Pharmacy (then the Royal Pharmaceutical Society) said: “The burden of managing medicines shortages for community pharmacies, general practice and hospitals remain unsustainably high.”
Read more: ‘What causes medicines shortages: the supply chain explained‘


